SalaryGuide
AboutPricingFor Employers

Marketing jobs

4 marketing jobs

UCB logo
3 weeks ago

Peer-to-Peer Marketing Lead Dermatology

UCB

Atlanta, GA (Hybrid)Other$164K/yr – $215K/yr
UCB logo
2 months ago

Digital Technology Lead, Omnichannel Marketing

UCB

Atlanta, GA (Hybrid)Permanent$148K/yr – $195K/yr
UCB logo
2 months ago

Peer-to-Peer Marketing Lead Dermatology

UCB

Atlanta, GA (Hybrid)Full time$164K/yr – $215K/yr
UCB logo
2 months ago

Peer-to-Peer Marketing Lead Dermatology

UCB

Atlanta, GA (Hybrid)Permanent$164K/yr – $215K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

4 jobs
UCB logo

Peer-to-Peer Marketing Lead Dermatology

UCB

Atlanta, GA (Hybrid)

$164K/yr - $215K/yrIn-houseOtherSenior level7+ years exp.
3 weeks ago
UCB logo

Digital Technology Lead, Omnichannel Marketing

UCB

Atlanta, GA (Hybrid)

$148K/yr - $195K/yrIn-housePermanentSenior level10+ years exp.
2 months ago
UCB logo

Peer-to-Peer Marketing Lead Dermatology

UCB

Atlanta, GA (Hybrid)

$164K/yr - $215K/yrIn-houseFull-timeSenior level7+ years exp.
2 months ago
UCB logo

Peer-to-Peer Marketing Lead Dermatology

UCB

Atlanta, GA (Hybrid)

$164K/yr - $215K/yrIn-housePermanentSenior level7+ years exp.
2 months ago
UCB logo
UCB

Peer-to-Peer Marketing Lead Dermatology

Atlanta, GA (Hybrid)

$164K/yr – $215K/yrSenior Level7+ years expOther

Posted 3 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own day-to-day HCP education program delivery and project management, ensure compliance, and collaborate with internal and external partners to advance the dermatology brand strategy.

Job Description

Responsibilities

  • Day to Day development and delivery of HCP educational tactical program efforts that enable the achievement of the overall brand strategy and defined metrics.
  • Define key performance standards and drive effective and efficient approaches in HCP education delivery.
  • Own day-to-day Peer to Peer operational & logistics required for effective Project Management of key initiatives (i.e. ANF & Quarterly Planning submissions, Ad board & Congress logistics)
  • Consistently apply industry best practices and ways of working to deliver leading HCP education.
  • Develops and maintain a keen understanding of the Dermatology business including customers, brand marketing for both the PSO and HS indications.
  • Operates at the highest level of UCB compliance and professional standards.

Requirements

  • Minimum 7 years’ experience in dermatology sales, marketing, KOL development and/or other directly related roles.
  • Overnight travel required. Up to 50% of time.

Preferred

  • Experience working successfully with commercial and clinical functions.
  • Proven experience in process building and project management.
  • Ability to interface and collaborate with a variety of external and internal partners in a highly professional manner, serving as the “face” of the company at key conference and events.
  • Strong influencing skills with those over whom there is no immediate supervisory capacity to achieve objectives.
  • Results oriented, attention to accuracy and detail, able to set priorities, take appropriate risks in a compliant manner.
  • Ability to interface with key customers, accounts, physicians, practitioners, industry contacts, and consultants, accomplish corporate objectives.
  • Ability to understand marketing terminology, trends and adjust accordingly.
  • Strong project management skills with the ability to manage multiple high priorities and evaluate results making go/no-go decisions.
  • Excellent interpersonal, oral, and written communication skills. Highly skilled in presenting in front of groups.
UCB logo

UCB

4.0 Glassdoor

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine.We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives.From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future.We're inspired by patients, driven by science.

Founded in 1928
Brussels, Brussels Region, BEL
14K employees (686 in marketing)
www.ucb.com
82% recommend to a friend
90% CEO approval

Traffic Signals

Monthly Visitors
154.3K
Traffic Source Mix
Search
52%
Direct
34.6%
Referral
8.4%
Social
4%
Paid
0.9%

Headcount Trend

Current headcount: ~14.3K

Marketing Team

Marketing Team Size
568 (4% of company)
Median Career Experience
18 years
Median Tenure
4.8 years
Marketing Roles Posted (Last 30 Days)
1

People

Marketing Leadership

Marcus Krause
Marcus Krause
Head of Marketing - Rheumatology
At the company for 18 years 3 months
Caroline Hawkins
Caroline Hawkins
Head of Mito Disease/Tk2d Marketing, US
At the company for 3 years 2 months
Jennifer Tolley
Jennifer Tolley
Head of Omnichannel and Digital Marketing
At the company for 3 years 2 months
Bipan Singh
Bipan Singh
Head of Marketing- Rare Syndrome (Developmental Epileptic Encephalopathies)
At the company for 7 years 7 months

Funding

Total Funding
$201.8M
Last Raise
$101M
Post IPO Equity, 4 years ago

Funding History

  • May 2022
    Post IPO Equity • $101M
  • May 2015
    Post IPO Equity • $787.6K
  • Dec 2009
    Post IPO Equity • $100M

Recent News

Grâce à UCB et argenx, le Bel 20 passe le cap des 5 000 points pour la première fois de son histoire
Oct 16, 2025 • La Libre.be
L’action UCB a quadruplé en deux ans, a-t-elle encore du jus?
Oct 14, 2025 • L'Echo
Bourse: mais où s’arrêtera UCB ?
Oct 8, 2025 • Trends-Tendances
UCB investit plus de CHF 100 millions à Bulle
Oct 7, 2025 • Greater Geneva Bern area
Année faste pour UCB Biopharma, l’entreprise familiale à la plus grande valeur ajoutée
Oct 2, 2025 • Trends-Tendances
Très bonne nouvelle pour le Bimzelx d’UCB
Oct 1, 2025 • Testachats
La Bourse de Bruxelles refranchit les 4.800 points, l'action UCB progresse toujours
Sep 30, 2025 • La Libre.be
Bourse de Bruxelles - Le titre UCB s'envole à près de 18% peu après l'ouverture de la Bourse
Sep 29, 2025 • DHnet
L'action UCB s'envole et atteint un nouveau record après l'échec d'un concurrent
Sep 29, 2025 • L'Echo
"L'échec" d'un concurrent fait flamber UCB de près de 17 % en Bourse
Sep 29, 2025 • La Libre.be
Les actions UCB et argenx finalement peu impactées par les droits de douane de 100% de Trump
Sep 26, 2025 • L'Echo
Rheumatoid Arthritis Therapeutics Market Trends Analysis Report 2025-2033 by Molecule (Pharmaceuticals, Biopharmaceuticals), by Sales Channel (Prescription, Over-the-Counter)
Sep 26, 2025 • Research and Markets
L'envolée d'Umicore ne compense pas la chute d'UCB à la Bourse de Bruxelles
Sep 25, 2025 • La Libre.be
Belgium hopes to boost projects in biotech, life sciences with S. Korea
Sep 21, 2025 • Korea Herald
BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
Sep 17, 2025 • Morningstar.com
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
Sep 17, 2025 • Morningstar.com
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
Sep 17, 2025 • PR Newswire
Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight
Sep 17, 2025 • PR Newswire
UCB’s Bimzelx continues to improve HS outcomes at three years
Sep 17, 2025 • Pharma Letter
MoonLake, le facteur qui pourrait bientôt secouer l'action UCB de 10% "à la hausse ou à la baisse"
Sep 12, 2025 • L'Echo
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care
Sep 10, 2025 • PR Newswire
Enhanced Access to gMG Treatments: UCB Canada Secures pCPA Agreements for ZILBRYSQ® and RYSTIGGO® Français
Sep 9, 2025 • Canada NewsWire
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Aug 29, 2025 • Canada NewsWire
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Aug 29, 2025 • prnasia.com
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Aug 29, 2025 • BioSpace
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Aug 29, 2025 • MarketScreener
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Aug 29, 2025 • PR Newswire UK
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Aug 28, 2025 • Morningstar.com
Le Bel 20 en vert | Avis de brokers sur UCB, Kinepolis et Deceuninck | Positions "short" sur Lotus et Melexis (+Briefing)
Aug 25, 2025 • L'Echo
Argenx poised to expand Vyvgart market off new phase 3 data
Aug 25, 2025 • pharmaphorum
UCB tourne à plein régime
Aug 22, 2025 • Trends-Tendances
UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
Aug 5, 2025 • PR Newswire
UCB relève ses prévisions annuelles en dépit des menaces aux États-Unis
Jul 31, 2025 • L'Echo
Le groupe pharma UCB vise un chiffres d'affaires record, l'action s'envole
Jul 31, 2025 • La Libre.be
Le Bel 20 en hausse | Avis de brokers sur UCB, Elia et Proximus | Nyxoah grimpe (+Briefing)
Jul 29, 2025 • L'Echo
Dermatological Drugs Market Forecast to 2034 – For Business Leaders, Analysts, and Strategic Teams
Jul 29, 2025 • EIN Presswire
U.S. Zilbrysq (Zilucoplan) Market Research Report 2025-2030 | Zilbrysq Secures Competitive Edge with No Direct SC C5 Competitors
Jul 28, 2025 • Research and Markets
CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight
Jul 24, 2025 • PR Newswire UK
CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight
Jul 24, 2025 • PR Newswire
Lennox Gastaut Syndrome Market Research Report 2025-2035 | Regulatory Agencies Streamline Approval for Cutting-Edge Therapies, Pharmaceuticals Advance Novel AEDs
Jul 22, 2025 • Research and Markets
Chronic Plaque Psoriasis Market Analysis and Forecast Report 2025-2035 | Personalized Medicine Fuels Chronic Plaque Psoriasis Treatment Advances
Jul 21, 2025 • Research and Markets
Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight
Jul 21, 2025 • PR Newswire UK
UCB initiated with bullish view at Goldman Sachs, here's why
Jul 16, 2025 • thefly.com
Eight rare autoimmune diseases biotechs are fighting to treat
Jul 16, 2025 • Labiotech.eu
Europe Pharmaceutical Drugs Market Expands with R&D Innovation, Biologics Growth, and Regulatory Harmonization 2025–2032
Jul 10, 2025 • EIN Presswire
UCB secoué par les nouvelles menaces de Trump sur la pharma
Jul 9, 2025 • L'Echo
Genomenon and UCB Partner to Advance Thymidine Kinase 2 Deficiency Awareness and Diagnosis
Jul 9, 2025 • PR Newswire
UCB presents latest research advancements at European Pediatric Neurology Society Congress
Jul 8, 2025 • PharmiWeb
UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community
Jul 8, 2025 • PR Newswire
UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community
Jul 8, 2025 • Morningstar.com
Keloid Market Size to Reach USD 356.3 Million by 2035 - Epidemiology Report by IMARC Group
Jul 4, 2025 • EIN Presswire
iQure Pharma Appoints Former UCB Chief Medical Officer and Head of Development, Prof. Iris Loew-Friedrich, MD, as Clinical and R&D Advisor
Jul 2, 2025 • PR Newswire
Lennox Gastaut Syndrome Report 2025 – For Strategy Officers and Market Intelligence Teams
Jul 1, 2025 • EIN Presswire
UCB announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency Disorder
Jun 30, 2025 • PharmiWeb
Real-World Evidence Market To Surpass USD 5.27 bilion 2032, to Grow at a CAGR of 14.3 % From 2025 To 2032
Jun 30, 2025 • EIN Presswire
UCB reports success in phase 3 study of fenfluramine for CDD
Jun 30, 2025 • Pharma Times
UCB reports positive results from Phase 3 study of fenfluramine in CDKL5
Jun 27, 2025 • thefly.com
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
Jun 27, 2025 • PR Newswire
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
Jun 27, 2025 • Morningstar.com
UCB: share up after positive phase 3 trial
Jun 27, 2025 • MarketScreener
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
Jun 27, 2025 • MarketScreener
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
Jun 27, 2025 • BioSpace
ALS: how close are we to a cure?
Jun 25, 2025 • Labiotech.eu
Crohn's Disease Market Size in the 7MM Expected to Reach USD 12,052.2 Million by 2035
Jun 25, 2025 • EIN Presswire
Ankylosing Spondylitis Market to Reach $8.1 Billion by 2030
Jun 25, 2025 • EIN Presswire
UCB, Bangladesh Bank launch entrepreneurship development program under SICIP in Bogra
Jun 25, 2025 • Business - Dhaka Tribune
"Achetez UCB" | Avis de brokers sur VGP, Shurgard, Hyloris, AB InBev, D'Ieteren et Deme | Sequana bondit (+Briefing)
Jun 23, 2025 • L'Echo
UCB just upgraded at Morgan Stanley, here's why
Jun 23, 2025 • thefly.com
UCB jumps over 4% after Morgan Stanley upgrades to “overweight”
Jun 23, 2025 • Investing.com
UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference
Jun 20, 2025 • BioSpace
UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference
Jun 20, 2025 • PR Newswire
UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference
Jun 20, 2025 • Morningstar.com
UCB to present research on TK2d at UMDF 2025 Conference
Jun 20, 2025 • thefly.com
Parkinson's disease Drug Market | Forecasted to Cross Valuation of $10.4 Billion by 2031
Jun 19, 2025 • EIN Presswire
UCB ne parvient pas à rassurer les investisseurs
Jun 13, 2025 • L'Echo
UCB investit deux milliards de dollars dans des capacités de production aux États-Unis
Jun 12, 2025 • L'Echo
UCB annonce un investissement record de deux milliards de dollars aux États-Unis
Jun 12, 2025 • La Libre.be
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
Jun 12, 2025 • PharmiWeb
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
Jun 12, 2025 • BioSpace
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
Jun 12, 2025 • Biogen Inc.
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
Jun 12, 2025 • MarketScreener
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
Jun 12, 2025 • MarketScreener
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
Jun 11, 2025 • Morningstar.com
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
Jun 11, 2025 • PR Newswire
Top Growth Driver In The Psoriasis Market 2025: Growing Geriatric Population Boosting Market
May 23, 2025 • EIN Presswire
Dépollution du site UCB au Roeulx : Il faudra compter encore trois ans de travaux, mais pas avant l'été 2026
May 14, 2025 • DHnet
Real-world evidence for romosozumab in high-risk fracture patients
Apr 14, 2025 • Pharma Letter
European, Indian pharma shares singed as Trump threatens tariffs again
Apr 9, 2025 • MarketScreener
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Apr 9, 2025 • Benzinga.com
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
Apr 3, 2025 • BioSpace
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
Apr 3, 2025 • PR Newswire
UCB presents key data from Alzheimer’s and Parkinson’s disease research programs at AD/PD 2025
Apr 1, 2025 • PharmiWeb
[Pr]RYSTIGGO® Now Approved for Adults with Generalized Myasthenia Gravis (gMG) in Canada
Apr 1, 2025 • BioSpace
Nyxoah résiste | UCB sous pression | Avis de brokers sur Ageas, D'Ieteren et Syensqo (+Briefing)
Mar 26, 2025 • L'Echo
Anterior Uveitis Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034
Mar 24, 2025 • EIN Presswire
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
Mar 19, 2025 • PR Newswire
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
Mar 19, 2025 • PharmiWeb.com
UCB subit sa plus lourde chute boursière depuis mai 2022
Mar 10, 2025 • L'Echo
"Promesses tenues" : UCB ravit ses investisseurs et décolle en Bourse
Mar 3, 2025 • La Libre.be
Le chiffre d'affaires d'UCB a franchi la barre des 6 milliards d'euros en 2024
Feb 27, 2025 • L'Echo